Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
Conditions
Interventions
mRNA-1893
Placebo
Locations
4
United States
Meridan Clinical Research
Omaha, Nebraska, United States
Benchmark Research
Austin, Texas, United States
Benchmark Research
Fort Worth, Texas, United States
Ponce School of Medicine - CAIMED Center
Ponce, Puerto Rico
Start Date
July 30, 2019
Primary Completion Date
March 22, 2021
Completion Date
March 22, 2021
Last Updated
August 21, 2024
NCT03624946
NCT03443830
Lead Sponsor
ModernaTX, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions